The most profitable SDG to date is SDG #3: "Good Health & Well Being" (vaccines / biotech / data).

https://www.gavi.org/our-alliance/global-health-development/sustainable-development-goals

I believe you’ll conclude what kind of conspiracy theory view of the world you hold by the time the first 3.5min of this interview is heard.
Very interesting indeed.
The interviewer, John Kirby, has a very good.
Best wishes
Mike

Dr Mike Yeadon

https://www.bitchute.com/video/uRkSUA3V5V2L/

This is an important paper & it’s importance rests on its findings utterly demolishing, once & for all, that “lockdowns” do not save lives, while applying hideous damage to everything we hold dear in life.
It obliterated the case for lockdowns, period.
Best wishes,
Mike

Dr Mike Yeadon

https://www.tandfonline.com/doi/full/10.1080/13571516.2021.1976051

LOCKDOWNS INCREASE TRANSMISSION OF RESPIRATORY VIRUSES, THEY DO NOT DECREASE CASES

"In the framework of this analysis, there is no evidence that more restrictive nonpharmaceutical interventions (‘lockdowns’) contributed substantially to bending the curve of new cases in England, France, Germany, Iran, Italy, the Netherlands, Spain or the United States in early 2020. By comparing the effectiveness of NPIs on case growth rates in countries that implemented more restrictive measures with those that implemented less-restrictive measures, the evidence points away from indicating that mrNPIs provided additional meaningful benefit above and beyond lrNPIs. While modest decreases in daily growth (under 30%) cannot be excluded in a few countries, the possibility of large decreases in daily growth due to mrNPIs is incompatible with the accumulated data.

The direction of the effect size in most scenarios points towards an increase in the case growth rate, though these estimates are only distinguishable from zero in Spain (consistent with nonbeneficial effect of lockdowns). Only in Iran do the estimates consistently point in the direction of additional reduction in the growth rate, yet those effects are statistically indistinguishable from zero.

While it is hard to draw firm conclusions from these estimates, they are consistent with a recent analysis that identified increased population-level transmission and cases in Hunan, China, during the period of stay-at-home orders, attributed to increased intra-household density and transmission.

In other words, it is possible that stay-at-home orders may facilitate transmission if they increase person-to-person contact where transmission is efficient such as closed spaces. "

https://onlinelibrary.wiley.com/doi/full/10.1111/eci.13484

Scathing open letter to Canadian authorities!
Mike

On Merck's Covid-19 drug, "the orally available prodrug form of
rNHC, molnupiravir (EIDD-2801 or MK-4482)".

Shuntai Zhou et al., "β-d-N4-hydroxycytidine Inhibits SARS-CoV-2
Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells,"
The Journal of Infectious Diseases 224, no. 3 (August 2021),
https://doi.org/10.1093/infdis/jiab247

"Due to their mechanism of action, mutagenic ribonucleoside analogs
could be metabolized by the host cell.. The concern would be that mutations in host DNA could contribute to the
development of cancer, or cause birth defects either in a developing
fetus or through incorporation into sperm precursor cells." ...

"It seems unlikely that a short course of therapy would spare the host
from this exposure because both RNA precursors that affect the virus
and DNA precursors that would affect the host pass through the common
ribonucleoside diphosphate intermediate."

On Merck's Covid-19 drug, "the orally available prodrug form of
rNHC, molnupiravir (EIDD-2801 or MK-4482)".

"We previously showed that ?-D-N4-hydroxycytidine (rNHC) and its orally bioavailable prodrug, molnupiravir, acts as a broad-spectrum antiviral against coronaviruses in vitro and in vivo through lethal mutagenesis. Molnupiravir is currently in clinical trials for the treatment of SARS-CoV-2 infection. However, there are concerns that rNHC could be metabolized to dNHC and cause mutations in host cells. 

rNHC showed a dose-dependent inhibition and mutagenic effect of SAR-CoV-2 in vitro. However, rNHC would be expected to be metabolized into the deoxynucleotide pool (by host RNR), resulting in DNA mutation of dividing mammalian cells. We demonstrated such mutagenic potential in a simple mammalian cell detection scheme. Molnupiravir has considerable potential as an orally bioavailable direct acting antiviral against SARS-CoV2 early in infection [Really..what about Ivermectin instead?], especially in high risk patients. However, clinical use should be carefully considered in light of its potential mutagenic effects on the host."

https://www.croiconference.org/abstract/rnhc-inhibits-sars-cov-2-in-vitro-but-is-mutagenic-in-mammalian-cells/